G Gakis
Overview
Explore the profile of G Gakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
170
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niegisch G, Bolenz C, Doehn C, Gakis G, Hartmann A, Muller-Huesmann H, et al.
Urologie
. 2024 Aug;
63(10):1019-1027.
PMID: 39186130
The risk of recurrence in patients with muscle invasive bladder cancer (MIBC) after radical cystectomy depends on the pathological tumor stage. In particular, patients with lymph node metastasis (pN+), locally...
2.
Kramer M, Gakis G
Urologe A
. 2020 May;
59(7):784-789.
PMID: 32468091
High-risk nonmuscle invasive bladder cancer (HR NMIBC) is an immunological malignancy. The standard therapy for HR NMIBC is based on transurethral bladder tumor resection with adjuvant Bacillus Calmette Guérin (BCG)...
3.
Distler F, Pahernik S, Gakis G, Hutterer G, Lebentrau S, Rink M, et al.
World J Urol
. 2019 Dec;
38(10):2523-2530.
PMID: 31834472
Objectives: To validate the adherence of urologists to chemotherapy recommendations given in the EAU guidelines on PeCa. The European Association of Urology (EAU) guidelines on penile cancer (PeCa) are predominantly...
4.
Horwich A, Babjuk M, Bellmunt J, Bruins H, de Reijke T, De Santis M, et al.
Ann Oncol
. 2019 Nov;
30(11):1697-1727.
PMID: 31740927
Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary...
5.
Hupe M, Gakis G, Seiler R
Urologe A
. 2019 Jun;
58(7):760-767.
PMID: 31172245
Background: Molecular tumor boards (MTB) are becoming more common. There are several molecular alterations in urothelial cancer a molecular tumor board can potentially rely on. Objectives: The aim is to...
6.
Gakis G, Volkmer B, Qvick B, Marteau F, Stenzl A
Urologe A
. 2018 Apr;
58(1):34-40.
PMID: 29637215
Background: Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transurethral resection of...
7.
Sim A, Todenhofer T, Mischinger J, Fahmy O, Boettge J, Rausch S, et al.
Int Braz J Urol
. 2016 Aug;
42(4):856-7.
PMID: 27564306
Objective: Vascular involvement in the form of renal vein (RV) or inferior vena cava (IVC) thrombus can be seen in 4-10% of patients presented with RCC. In patients without presence...
8.
Kaufmann S, Amend B, Kruck S, Gakis G, Bedke J, Horger M
Rofo
. 2015 Jul;
187(8):623-7.
PMID: 26218471
No abstract available.
9.
Gakis G, Morgan T, Daneshmand S, Keegan K, Todenhofer T, Mischinger J, et al.
Ann Oncol
. 2015 May;
26(8):1754-9.
PMID: 25969370
Background: To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC). Patients And Methods: A series of 124 patients (86 men, 38 women) were diagnosed with and...
10.
Gakis G, Stenzl A, Horn T, Gschwend J, Otto W, Burger M
Urologe A
. 2015 Mar;
54(4):491-8.
PMID: 25802103
Background: Non-muscle-invasive bladder cancer with a low-grade differentiation represents a special challenge. Method: Although urine cytology is still the most reliable and effective urine-based marker and there are no substantial...